Camp4 Therapeutics (CAMP) investor relations material

Executive summary

• Submitted first regulatory filing for CMP-002 in Australia, with global filings and Phase 1/2 trial initiation planned for H2 2026; EMA granted orphan drug designation and FDA application is pending.

• Proprietary RAP Platform enables rapid identification of regulatory RNAs for gene upregulation, focusing on CNS diseases and expanding through strategic partnerships.

• Entered collaboration with CURE SYNGAP1 to support the ProMMIS natural history study and advance SYNGAP1 research.

• Cash runway expected into 2028, with $99.2M in cash and cash equivalents as of March 31, 2026.

• Appointed Michael MacLean to the Board of Directors.

Financial highlights

• Revenue for Q1 2026 was $1.3M, up from $0.9M in Q1 2025, mainly from collaborations.

• Net loss for Q1 2026 was $18.3M, compared to $12.4M in Q1 2025, driven by R&D, G&A expenses, and a $6.2M non-cash derivative tranche liability expense.

• Cash and cash equivalents as of March 31, 2026 were $99.2M, down from $109.5M at December 31, 2025; accumulated deficit reached $310.5M.

• Operating cash outflow for Q1 2026 was $11.0M, improved from $14.3M in Q1 2025.

• R&D expenses were $10.2M and G&A expenses were $4.2M for Q1 2026.

Outlook and guidance

• Cash position expected to fund operations into 2028 based on current plans.

• Anticipates increased expenses as clinical and preclinical programs advance, with additional funding likely needed for long-term growth.

• Plans additional global regulatory filings and initiation of global Phase 1/2 clinical trial for CMP-002 in H2 2026.